Ceptaris Therapeutics, Inc. Announces Publication in JAMA Dermatology of Positive Clinical Results for Mechlorethamine Gel in Early Stage Mycosis Fungoides, the Most Common Type of Cutaneous T-Cell Lymphoma

MALVERN, Pa.--(BUSINESS WIRE)--Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the results of a pivotal trial comparing its proprietary gel formulation of mechlorethamine hydrochloride 0.02% to pharmacy-compounded mechlorethamine ointment for the treatment of early stage mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), have been published in JAMA Dermatology (formerly Archives of Dermatology).1